Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Chunli Medical (01858.HK) by 434,800 shares on October 27, 2025, marking a 1.00% increase [1][2] - Over the past five trading days, southbound funds have increased their holdings for five days, with a total net increase of 1,522,600 shares [1][2] - In the last 20 trading days, there have been 13 days of increased holdings by southbound funds, resulting in a cumulative net increase of 539,900 shares [1][2] Group 2 - As of now, southbound funds hold a total of 43,726,200 shares of Chunli Medical, which accounts for 45.95% of the company's total issued ordinary shares [1][2] - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with main products including joint prosthetics and spinal implants [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, while its spinal implant products include a full range of spinal fixation systems [2]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a positive performance with a closing price of 26.28 yuan, reflecting a 1.08% increase on October 27, 2025, amidst varying fund flows from different investor categories [1][2]. Group 1: Stock Performance and Fund Flow - On October 27, 2025, Chunli Medical's stock recorded a trading volume of 23,400 hands and a transaction value of 61.7974 million yuan [1]. - The net inflow of main funds was 4.5142 million yuan, accounting for 7.3% of the total transaction value, while retail investors experienced a net outflow of 7.5814 million yuan, representing 12.27% of the total [1]. - Over the past five days, the stock has seen fluctuations in fund flows, with significant retail outflows on October 24 and 23, indicating varying investor sentiment [1]. Group 2: Company Financials and Industry Comparison - Chunli Medical's total market capitalization is 10.08 billion yuan, with a net asset value of 2.909 billion yuan and a net profit of 114 million yuan [2]. - The company reported a year-on-year revenue increase of 28.27% to 488 million yuan and a net profit increase of 44.85% to 114 million yuan for the first half of 2025 [2]. - The gross profit margin stands at 67.09%, significantly higher than the industry average of 51.35%, indicating strong operational efficiency [2]. Group 3: Analyst Ratings and Market Sentiment - In the last 90 days, eight institutions have rated Chunli Medical, with seven giving a "buy" rating and one an "accumulate" rating, reflecting positive market sentiment [3]. - The average target price set by institutions for the stock is 30.61 yuan, suggesting potential upside from the current trading price [3].

截至2025年10月24日收盘，春立医疗（688236）报收于26.0元，较上周的24.85元上涨4.63%。本周，春 立医疗10月22日盘中最高价报28.77元，股价触及近一年最高点。10月20日盘中最低价报24.34元。春立 医疗当前最新总市值99.73亿元，在医疗器械板块市值排名38/126，在两市A股市值排名1867/5160。 H股公告：董事会会议通告 北京市春立正达医疗器械股份有限公司董事会宣布将于2025年10月30日举行董事会会议，旨在批准公司 及其附属公司截至2025年9月30日止九个月的第三季度业绩公布，并考虑派付中期股息（如有）。该公 告由董事长史文玲代表董事会发布，日期为2025年10月22日，地点为中国北京。截至公告日期，执行董 事为史文玲女士、史春宝先生、岳术俊女士及解凤宝先生；非执行董事为王鑫先生；独立非执行董事为 徐泓女士、黄德盛先生及翁杰先生。香港交易所及香港联交所对本公告内容的准确性或完整性不承担责 任，且不就依赖该等内容引致的任何损失承担任何责任。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - Southbound funds increased their holdings in Chunli Medical (01858.HK) by 269,900 shares on October 24, 2025, marking a 0.63% change [1][2] - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 942,600 shares [1][2] - In the last 20 trading days, there have been 13 days of net increases in holdings by southbound funds, totaling 1,614,000 shares [1][2] Group 2 - As of now, southbound funds hold 43,291,400 shares of Chunli Medical, which represents 45.49% of the company's total issued ordinary shares [1][2] - Chunli Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics and spinal implants [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, while its spinal implant products include a full range of spinal fixation systems [2]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight decline, with significant net outflows from major and retail investors, while the company has reported strong revenue and profit growth in its recent financial results [1][3]. Financial Performance - As of October 24, 2025, Chunli Medical's stock closed at 26.00 yuan, down 0.23% with a trading volume of 23,300 hands and a transaction value of 60.32 million yuan [1]. - The company reported a main revenue of 488 million yuan for the first half of 2025, a year-on-year increase of 28.27%, and a net profit of 114 million yuan, up 44.85% year-on-year [3]. - In Q2 2025, the company achieved a single-quarter main revenue of 258 million yuan, a 62.85% increase year-on-year, and a net profit of approximately 56.4 million yuan, up 136.7% year-on-year [3]. Market Position and Ratios - Chunli Medical's total market value is 9.973 billion yuan, with a net asset of 2.909 billion yuan and a net profit of 114 million yuan [3]. - The company's price-to-earnings ratio (P/E) is 43.56, significantly lower than the industry average of 103.78, while its price-to-book ratio (P/B) stands at 3.43, also lower than the industry average of 3.79 [3]. - The gross margin is reported at 67.09%, which is higher than the industry average of 51.33%, and the net margin is 23.48%, compared to the industry average of 10.4% [3]. Investor Sentiment - Over the past 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set at 30.61 yuan [4]. - On October 24, 2025, the net outflow of major funds was 8.91 million yuan, accounting for 14.76% of the total transaction value, while retail investors saw a net inflow of 10.12 million yuan, representing 16.78% of the total transaction value [1][2].

Group 1 - The core point of the article highlights the increase in southbound capital holdings in Chunli Medical (01858.HK), with a net increase of 7.29 thousand shares on October 23, 2025 [1] - Over the past five trading days, southbound capital has increased holdings on three occasions, totaling a net increase of 3.84 thousand shares [1] - In the last twenty trading days, there have been thirteen days of increased holdings, with a cumulative net increase of 3.78 thousand shares [1] Group 2 - As of October 23, 2025, southbound capital holds 43.02 million shares of Chunli Medical, representing 45.21% of the company's issued ordinary shares [1] - The total number of shares held by southbound capital has fluctuated, with a notable increase of 62.23 thousand shares on October 22, 2025, and a decrease of 63.42 thousand shares on October 17, 2025 [2] - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics and spinal implants [2]

Group 1 - The core viewpoint of the news is that Spring Medical's stock experienced a slight decline of 1.03% on October 22, with a trading volume of 155 million yuan, indicating a relatively stable market presence despite the drop [1] - On October 22, Spring Medical had a financing buy-in amount of 19.35 million yuan and a financing repayment of 18.11 million yuan, resulting in a net financing buy of 1.24 million yuan, with a total financing and securities balance of 43.62 million yuan as of the same date [1] - The financing balance of Spring Medical, which stands at 43.62 million yuan, accounts for 0.56% of its circulating market value and is above the 90th percentile level over the past year, indicating a high level of financing activity [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - As of June 30, Spring Medical reported a revenue of 488 million yuan for the first half of 2025, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, reflecting a 44.85% increase compared to the previous year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 3 - As of June 30, 2025, the number of shareholders in Spring Medical decreased by 17.57% to 5,920, while the average circulating shares per person increased by 341.41% to 48,836 shares [2] - Among the top ten circulating shareholders, Ping An Low Carbon Economy Mixed A (009878) is the fourth largest with 3.77 million shares, an increase of 2.77 million shares from the previous period, while Southern Medical Health Flexible Allocation Mixed A (000452) is a new entrant as the ninth largest shareholder with 1.60 million shares [3]

Core Points - Spring Medical experienced a decline of 5.11% on October 23, with a stock price of 25.43 CNY per share and a total market capitalization of 9.754 billion CNY [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [1] - The main revenue source for the company is medical device products, accounting for 99.89% of total revenue, with a minor contribution from other sources [1] Company Overview - Spring Medical was established on February 12, 1998, and went public on December 30, 2021 [1] - The company's products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) entered the top ten circulating shareholders, holding 1.603 million shares, which is 0.42% of the circulating shares [2] - The fund has reported a year-to-date return of 43.9% and a one-year return of 27.37% [2] Fund Management - The fund manager of Southern Medical Health Flexible Allocation Mixed A is Cai Qiang, who has been in the position for 2 years and 131 days [3] - The total asset size of the fund is 4.213 billion CNY, with the best return during Cai's tenure being 21.91% [3]

Core Insights - The stock of Chunli Medical (688236) closed at 26.8 yuan on October 22, 2025, down by 1.03% with a trading volume of 56,000 hands and a transaction amount of 155 million yuan [1] Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, an increase of 28.27% year-on-year [3] - The net profit attributable to shareholders was 114 million yuan, up 44.85% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 258 million yuan, a year-on-year increase of 62.85% [3] - The single-quarter net profit attributable to shareholders was 56.4 million yuan, up 136.7% year-on-year [3] - The company achieved a gross margin of 67.09% and a net margin of 23.48% [3] Market Position - Chunli Medical's total market capitalization is 10.28 billion yuan, ranking 37th in the medical device industry [3] - The company has a price-to-earnings ratio (P/E) of 44.9, which is lower than the industry average of 120.11 [3] - The price-to-book ratio (P/B) stands at 3.54, slightly below the industry average of 3.79 [3] Investment Sentiment - In the last 90 days, 8 institutions rated the stock, with 7 buy ratings and 1 hold rating [4] - The average target price set by institutions over the past 90 days is 30.61 yuan [4] Capital Flow - On October 22, 2025, the net inflow of main funds was 2.1672 million yuan, accounting for 1.4% of the total transaction amount [1][2] - Retail investors had a net inflow of 350,300 yuan, representing 0.23% of the total transaction amount [1][2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 史文玲 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 中國，北京，2025年10月22日 （股 份 代 號：1858） 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年10月30日（星期四）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年9月30日止九個月之第三季度業績公佈及考慮派付 中期股息（如有）。 代表董事會 北京市春立正達醫療器械股份有限公司 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 董事長 董事會會議通告 * 僅供識別 ...